MG
JAZZ icon

Mather Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Mather Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3K Hold
22
– – ﹤0.01% 1610
2026
Q1 		$4.16K Buy
+22
New +$3.85K ﹤0.01% 1602
2025
Q4 		– Sell
-22
Closed -$2.9K – 1162
2025
Q3 		$2.9K Buy
+22
New +$2.64K ﹤0.01% 1489
2025
Q2 		– Sell
-63
Closed -$7.82K – 1182
2025
Q1 		$7.82K Hold
63
– – ﹤0.01% 1309
2024
Q4 		$7.76K Buy
63
+49
+350% +$5.78K ﹤0.01% 1298
2024
Q3 		$1.56K Sell
14
-120
-90% -$13.2K ﹤0.01% 1517
2024
Q2 		$16.1K Buy
134
+41
+44% +$4.51K ﹤0.01% 1314
2024
Q1 		$11.4K Buy
+93
New +$11.4K ﹤0.01% 1165

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Mather Group's JAZZ Position: Q2 2026 in Review

Mather Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 22 shares worth $5.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Mather Group first reported a position in JAZZ in Q1 2024 and has held it in 8 quarters since. The position peaked at $16.1K in Q2 2024. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Mather Group held 22 shares of Jazz Pharmaceuticals worth $5.3K as of Q2 2026.
  • Mather Group left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1610 holding.
  • Mather Group first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Jazz Pharmaceuticals position peaked at $16.1K in Q2 2024.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.